Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Antidepressants. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN1213991C reveals a copper-catalyzed route for high-purity sertraline intermediates, offering significant cost reduction and supply chain reliability for API manufacturing.
Patent CN102942501A details a novel one-pot hydrogenation method for Agomelatine, offering high purity, reduced dimer impurities, and significant cost advantages for pharmaceutical manufacturing.
Patent CN101088985A details a high-yield, eco-friendly synthesis of Bupropion Hydrochloride via direct bromination, offering significant cost reduction and supply chain reliability for pharmaceutical manufacturers.
Patent CN101048396A details a mild cyclization method for citalopram and escitalopram, offering high purity and scalable manufacturing for reliable pharmaceutical intermediate suppliers.
Patent CN101792400A details a high-yield four-step route for Agomelatine, offering significant cost reduction in API manufacturing and enhanced supply chain reliability.
Patent CN104230852A details a palladium-free synthetic route for vortioxetine offering significant cost reduction and supply chain reliability for pharmaceutical manufacturing.
Novel four-step synthesis method ensures high yield and purity for vortioxetine hydrobromide. Reduces costs and simplifies supply chain for pharmaceutical manufacturers.
Advanced cyanide exchange and acylation purification method for high-purity citalopram. Reduces desmethyl impurities significantly for reliable pharmaceutical intermediate supply chains.
Novel process for Citalopram using 5-carboxy-2-benzo[c]furanone. Reduces heavy metal use and improves scalability for pharmaceutical manufacturing.
Patent CN102964287A reveals a greener Fischer indole route for Vilazodone intermediates, offering significant cost reduction in API manufacturing and enhanced supply chain reliability.
Patent CN111187264A introduces a resin-catalyzed cyclization for mirtazapine, eliminating sulfuric acid waste and simplifying purification for reliable pharmaceutical intermediate supply.
Patent CN107513048A details a high-yield synthetic route for deuterated Vortioxetine hydrobromate offering significant cost reduction and supply chain reliability for pharmaceutical intermediates manufacturing.
Patent CN1680374A reveals optimized hydrolysis for mirtazapine intermediates, offering significant cost reduction and scalable manufacturing for pharmaceutical supply chains.
Patent CN111533662B details a cost-effective synthesis of citalopram intermediates using accessible halogenated benzoic acids, offering significant supply chain advantages.
Patent CN1497048A details a biocatalytic route for chiral intermediates. Offers high ee and scalable production for pharma applications.
Advanced manufacturing route for Vilazodone intermediates utilizing microwave cyanation and efficient piperazine cyclization, offering high purity and scalable production for pharmaceutical supply chains.
Patent CN110172045B reveals a green synthesis route for tianeptine sodium intermediates using fixed-bed oxidation, offering significant cost reduction and supply chain stability for API manufacturers.
Novel patent CN102690224A details a cost-effective route for 3-(4-chlorobutyl)-1H-5-cyanoindole, replacing pyrophoric catalysts with stable reagents for scalable API production.
Patent CN102267985A reveals a scalable route for Vilazodone HCl, eliminating hazardous Lewis acids and precious metals for cost-effective pharmaceutical manufacturing.
Patent CN102964287B reveals a green Fischer indole route for 3-(4-chlorobutyl)-5-cyanoindole, offering safer API manufacturing and reduced supply chain risks.